New FDA Approvals for Lung Cancer, Myeloma

In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Ziftomenib given at 600 mg in combination with venetoclax/azacitidine produced high response rates in NPM1-mutated AML.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

More than half of evaluable patients in the phase 1/2 NEXICART-2 trial experienced organ responses following treatment with NXC-201.

Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.